Aytu Biopharma, Inc
AYTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385818
No open-market purchases or sales by Aytu Biopharma, Inc insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q2 2026, worth $10.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 38
- 13F valueReported value at the end of Q2 2026
- $8.25M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding AYTU, Q2 2026
No superinvestor reported holding AYTU at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Aytu Biopharma, Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Disbrow JarrettChief Business Officer | PPurchase | +16.7K | $1.50 | +$25.0K | +130.2%29.5K after | |
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Disbrow Joshua R.Chief Executive Officer | PPurchase | +66.7K | $1.50 | +$100.0K | +77.0%153.3K after | |
| Jun 9, 2025 (view filing)4:31 PM ET | Jun 6 | 3 days | Nantahala Capital Management, LLC and 2 others10% Owner | PPurchase | +4.00M | $1.50 | +$6.00M | –4.82M after | Derivative |
| Mar 3, 2025 (view filing) | Feb 28 | 3 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +15.0K | $1.30 | +$19.5K | +21.0%86.6K after | |
| Jun 20, 2023 (view filing) | Jun 16 | 4 days | Pyszczymuka GregChief Commerical Officer | PPurchase | +12.0K | $1.87 | +$22.4K | +120.8%21.9K after | |
| Jun 15, 2023 (view filing) | Jun 14 | 1 day | Disbrow Joshua R.Chief Executive Officer | PPurchase | +14.0K | $1.86 | +$26.0K | +24.3%71.6K after | |
| Dec 21, 2022 (view filing)9:17 AM ET | Dec 19 | 2 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +112.4K | $0.2229 | +$25.0K | +10.0%1.23M after | |
| Dec 21, 2022 (view filing)9:15 AM ET | Dec 19 | 2 days | Pyszczymuka GregChief Commercial Officer | PPurchase | +100.0K | $0.2448 | +$24.5K | +121.9%182.1K after | |
| Nov 28, 2022 (view filing)4:30 PM ET | Nov 18 | 10 days | Oki Mark KChief Financial Officer | PPurchase | +90.0K | $0.23 | +$20.7K | +90.0%190.0K after | Amended |
| Nov 28, 2022 (view filing)4:30 PM ET | Nov 18 | 10 days | Disbrow Joshua R.Chief Executive Officer | PPurchase | +222.0K | $0.237 | +$52.6K | +24.7%1.12M after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aytu Biopharma, Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1,086,812 | $2.34M | 0.14% | 00.0% | Unchanged |
| Stonepine Capital Management, LLC | 912,921 | $1.96M | 1.49% | +120,632+15.2% | Added |
| AWM Investment Company, Inc. | 619,574 | $1.33M | 0.12% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 261,146 | $561.5K | 0.00% | 00.0% | Unchanged |
| Crown Advisors Management, Inc. | 200,000 | $430.0K | 0.24% | +55,000+37.9% | Added |
| Diadema Partners LP | 148,546 | $319.4K | 0.11% | −204,531−57.9% | Reduced |
| Two Sigma Investments, LP | 105,326 | $226.5K | 0.00% | −16,647−13.6% | Reduced |
| Renaissance Technologies LLC | 104,823 | $225.4K | 0.00% | +11,100+11.8% | Added |
| Geode Capital Management, LLC | 93,647 | $201.4K | 0.00% | +1,011+1.1% | Added |
| Citadel Advisors LLC | 49,414 | $106.2K | 0.00% | +12,573+34.1% | Added |